Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$1.22 - $2.48 $1.66 Million - $3.38 Million
-1,364,032 Reduced 76.29%
424,027 $530,000
Q2 2022

Aug 15, 2022

SELL
$1.63 - $3.46 $205,088 - $435,340
-125,821 Reduced 6.57%
1,788,059 $4.22 Million
Q1 2022

May 16, 2022

SELL
$2.66 - $6.49 $3,040 - $7,418
-1,143 Reduced 0.06%
1,913,880 $5.93 Million
Q4 2021

Feb 14, 2022

BUY
$6.24 - $10.2 $9.94 Million - $16.3 Million
1,593,232 Added 495.11%
1,915,023 $12.2 Million
Q3 2021

Nov 15, 2021

BUY
$9.73 - $15.52 $3.13 Million - $4.99 Million
321,791 New
321,791 $3.21 Million

Others Institutions Holding PASG

About Passage BIO, Inc.


  • Ticker PASG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,463,200
  • Market Cap $28.3M
  • Description
  • Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...
More about PASG
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.